TG Therapeutics Inc

NASDAQ:TGTX   4:00:00 PM EDT
15.57
+0.13 (+0.84%)
6:34:30 PM EDT: $15.24 -0.33 (-2.11%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.40B
Current PE189.73
Forward PE N/A
2yr Forward PE 34.6
See more stats
Estimates Current Quarter
Revenue$54.57 Million
Adjusted EPS-$0.05
See more estimates
10-Day MA$15.58
50-Day MA$15.54
200-Day MA$14.52
See more pivots

TG Therapeutics Inc Stock, NASDAQ:TGTX

3020 Carrington Mill Boulevard, Suite 475, Morrisville, North Carolina 27560
United States of America
Phone: +1.212.554.4484
Number of Employees: 264

Description

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.